BATTITO uBeAt-powered closed-loop sTandardisaTion of beatIng heart-on-chip for reliable cardioTOxicity screening
- Coordinator
- Politecnico Di Milano, Italy
- Runs
- 1 September 2026 to 29 February 2028
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 2 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101334870
What the project is doing
In the project's own words, from its summary on CORDIS.
Drug-induced cardiotoxicity remains a primary cause of late-stage clinical attrition. Current preclinical safety assessments are focused heavily on electrophysiology assays and animal models and shows limited predictivity for human outcomes, largely failing to detect critical cardiac liabilities. Heart-on-Chip models represent a transformative New Approach Methodology (NAM) to address this gap. However, their routine industrial adoption is severely hindered by biological variability and a lack in standardisation.
Current Heart-on-Chip models undergo open-loop, fixed maturation protocols (e.g. via electro/mechanical training), resulting in high sample-to sample variability which creates baseline noise that obscures subtle toxicological signals. BATTITO aims to demonstrate the industrial feasibility of transforming our validated beating heart-on-chip (uHeart) into a self-standardising cardiac NAM. The platform relies on the proprietary uBeat technology, a breakthrough actuator patented by Politecnico di Milano (POLIMI) and licensed to BiomimX, which provides heartbeat like training to cardiac cells.
Building on the findings of the ERC Starting Grant EvOoC, which demonstrated that mechanobiological closed-loop feedback enhances tissue maturation, BATTITO will engineer an automated quality loop directly linking optical contractility readouts to the uBeat actuation controller. This autonomous adaptation of the training mechanical forces using the real-time functional state of each individual microtissue will force biological convergence toward a highly standardised functional window.
POLIMI will lead the complex mechatronic integration and the quantitative biological validation of standardisation metrics. Simultaneously, the industrial stakeholder BiomimX will execute market analysis, validate the workflow against industrial constraints, and draft the commercial exploitation roadmap. BATTITO will deliver an automated NAM platform for robust cardiotoxicity screening.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Politecnico Di Milano | Milano | Italy | Coordinator |
| Biomimx SRL | Milano | Italy | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI